Tyrosine

A phase 2 trial demonstrated that metastasis-directed radiotherapy without concurrent systemic therapy achieved a median progression-free survival of 34.0 months in patients with oligometastatic clear cell renal cell carcinoma.

Precision medicine oncology pharmacists have become essential members of multidisciplinary cancer care teams, contributing to targeted therapy selection, molecular tumor board discussions, and patient access to novel drug combinations.

ALLO-316, a novel CAR T-cell therapy targeting CD70, demonstrated a 33% confirmed objective response rate in patients with advanced clear cell renal cell carcinoma whose tumors expressed CD70 in at least 50% of cells.

The HELIOS trial revealed OTX-TKI was well-tolerated with no serious adverse events, with all diabetic retinopathy severity score improvements occurring in the treatment arm and all worsening in the sham arm.

• Flatiron Health will present over 15 research studies at ISPOR 2025, demonstrating how machine learning and AI can transform real-world oncology data into valuable evidence for regulatory decisions. • Key presentations include validation of ML-extracted response data from EHRs, analysis of real-world evidence acceptance by FDA and EMA, and introduction of a novel Japanese breast cancer database. • The company's research highlights the growing importance of real-world data in complementing traditional clinical trials and informing precision medicine approaches across diverse healthcare systems.